var data={"title":"Treatment protocols for bladder cancer","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Treatment protocols for bladder cancer</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-bladder-cancer/contributors\" class=\"contributor contributor_credentials\">Tim Brenner, PharmD, BCOP</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-bladder-cancer/contributors\" class=\"contributor contributor_credentials\">Shrina Duggal, PharmD, BCOP</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-bladder-cancer/contributors\" class=\"contributor contributor_credentials\">Jim Natale, PharmD, BCOP</a></dd><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-bladder-cancer/contributors\" class=\"contributor contributor_credentials\">Scott M Wirth, PharmD, BCOP</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-bladder-cancer/contributors\" class=\"contributor contributor_credentials\">John W Mucenski, PharmD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-bladder-cancer/contributors\" class=\"contributor contributor_credentials\">Michael E Ross, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/treatment-protocols-for-bladder-cancer/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Feb 14, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H14907009\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The following material represents a subset of chemotherapy regimens that are used for the treatment of patients with bladder cancer in the neoadjuvant, adjuvant, or metastatic setting. <strong>This is</strong> <strong>not an exhaustive list</strong>; it includes regimens that are considered by the authors and editors to be commonly used and important for the care of patients with bladder cancer. Additional regimens may be added over time, particularly as treatment for bladder cancer evolves.</p><p>This topic review is intended to provide only a listing of chemotherapy regimens. It does not address the appropriate context for use of these regimens in the care of patients with bladder cancer. Clinicians should refer to the individual disease-oriented topic reviews that discuss the use of these protocols in appropriate clinical situations:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=neoadjuvant-treatment-options-for-muscle-invasive-urothelial-bladder-cancer#H210939438\" class=\"medical medical_review\">&quot;Neoadjuvant treatment options for muscle-invasive urothelial bladder cancer&quot;, section on 'Neoadjuvant chemotherapy'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=adjuvant-chemotherapy-for-muscle-invasive-urothelial-carcinoma-of-the-bladder\" class=\"medical medical_review\">&quot;Adjuvant chemotherapy for muscle invasive urothelial carcinoma of the bladder&quot;</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>(See <a href=\"topic.htm?path=treatment-of-metastatic-urothelial-cancer-of-the-bladder-and-urinary-tract\" class=\"medical medical_review\">&quot;Treatment of metastatic urothelial cancer of the bladder and urinary tract&quot;</a>.)</p><p/><p>These tables are provided as examples of how to administer these regimens; there may be other acceptable methods. All chemotherapy regimens must be administered by clinicians who are trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</p><p class=\"headingAnchor\" id=\"H14907233\"><span class=\"h1\">REGIMENS</span></p><p class=\"headingAnchor\" id=\"H931770276\"><span class=\"h2\">GC (gemcitabine plus cisplatin)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F53016\" class=\"graphic graphic_table graphicRef53016 \">table 1</a>)</p><p class=\"headingAnchor\" id=\"H931770284\"><span class=\"h2\">MVAC (methotrexate plus vinblastine, doxorubicin, and cisplatin)</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F64950\" class=\"graphic graphic_table graphicRef64950 \">table 2</a>) </p><p class=\"headingAnchor\" id=\"H2045253986\"><span class=\"h2\">Dose-dense MVAC chemotherapy for advanced urothelial carcinoma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>(<a href=\"image.htm?imageKey=ONC%2F111814\" class=\"graphic graphic_table graphicRef111814 \">table 3</a>)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"topicVersionRevision\">Topic 85676 Version 11.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li><a href=\"#H14907009\" id=\"outline-link-H14907009\">INTRODUCTION</a></li><li><a href=\"#H14907233\" id=\"outline-link-H14907233\">REGIMENS</a><ul><li><a href=\"#H931770276\" id=\"outline-link-H931770276\">GC (gemcitabine plus cisplatin)</a></li><li><a href=\"#H931770284\" id=\"outline-link-H931770284\">MVAC (methotrexate plus vinblastine, doxorubicin, and cisplatin)</a></li><li><a href=\"#H2045253986\" id=\"outline-link-H2045253986\">Dose-dense MVAC chemotherapy for advanced urothelial carcinoma</a></li></ul></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ONC/85676|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ONC/53016\" class=\"graphic graphic_table\">- Gemcitabine and cisplatin for metastatic urothelial cancer</a></li><li><a href=\"image.htm?imageKey=ONC/64950\" class=\"graphic graphic_table\">- MVAC regimen</a></li><li><a href=\"image.htm?imageKey=ONC/111814\" class=\"graphic graphic_table\">- Dose-dense MVAC chemotherapy for advanced urothelial carcinoma</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=adjuvant-chemotherapy-for-muscle-invasive-urothelial-carcinoma-of-the-bladder\" class=\"medical medical_review\">Adjuvant chemotherapy for muscle invasive urothelial carcinoma of the bladder</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=neoadjuvant-treatment-options-for-muscle-invasive-urothelial-bladder-cancer\" class=\"medical medical_review\">Neoadjuvant treatment options for muscle-invasive urothelial bladder cancer</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-metastatic-urothelial-cancer-of-the-bladder-and-urinary-tract\" class=\"medical medical_review\">Treatment of metastatic urothelial cancer of the bladder and urinary tract</a></li></ul></div></div>","javascript":null}